Kendle International 8K Regulation FD Disclosure | KNDL 12 Jan 09

27th Annual J.P. Morgan

Healthcare Conference

San Francisco, California

Jan.12, 2009

Exhibit 99.1

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Safe harbor

Information herein contains forward-looking statements pursuant to the safe harbor

provision of the Private Securities Litigation Reform Act of 1995. All such forward-looking

statements are based largely on management’s expectations and are subject to risks and

uncertainties that could cause actual results to differ materially. These risks and

uncertainties include competitive factors, outsourcing trends, contract terms, exchange

rate fluctuations, the Company’s ability to manage growth and to continue to attract and

retain qualified personnel, the Company’s ability to complete acquisitions and to integrate

newly acquired businesses and consolidation within the industry and other factors

described in the Company’s filings with the Securities and Exchange Commission.

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Today’s agenda

•

2008 Financial update

•

Strategic alignment

•

Market challenges and pharma

response

•

Market challenges and Kendle response

•

Summary

2008 Financial update

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

2008 year-to-date performance

Amounts in millions

as of 12/31/07

*** as of 9/30/08

YTD 2007

YTD 2008

Percentage

increase

Net service revenues

$293.3

$365.9

25%

Operating margin

12.8%

12.5%

EPS

$0.83

$1.63

98%

Backlog

$869**

$1,000***

16%

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

2008 Guidance

Amounts in millions

2007

2008 est

Growth

Net service revenues*

$398

$485 –

$500

22% –

26%

EPS

$1.26

$2.10 –

$2.25

67% –

79%

Strategic alignment

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Our vision

“Best-in-class”

provider of clinical

development services to the biopharmaceutical

industry through broad therapeutic

and geographic expertise

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Strategic alignment

Market

Operational

continuity and

leverage via

the matrix

Customer

and business

expansion to

accelerate

growth

Infrastructure

growth to

drive global

connectivity

Market

challenges

and

pharma

response

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Market challenges and pharma response

Challenge

Response

Examples

Therapeutic

rationalization

Supplier

rationalization

Recession

environment

Focus on therapeutic segments

Move to use of global CROs (narrowed

provider list)

Development of FSPs

Move to strategic outsourcing

R&D productivity

declining

Focus on core

competency

Managing costs

Increased outsourcing

Innovative, collaborative relationships

Increased communication with

experienced providers

Patient access

Moving R&D to

emerging markets

Leveraging footprint of

global CROs

A c c e l e r a t i o n

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Kendle: shaping the debate

•

How will customers of varying sizes embrace emerging outsourcing

models?

•

How will the CRO landscape/environment evolve in response to outsourcing

practice changes?

–

What changes will various CRO service providers implement as drug developers

transition to more alliance relationships?

•

What external factors on the horizon will most influence the transition to

partnership outsourcing models?

•

What do CROs

need to do to aid and accelerate this transition?

•

What is the quantifiable impact of different relationship types on drug

development performance?

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Current CRO market environment

Opportunity

6 to 12 months

Visibility

3 to 6 months

Short term visibility, long term opportunity

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

R&D spending in pharma

industry

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

CRO

revenues

from

publicly

traded

companies

Market challenges and Kendle response

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Market challenges and Kendle response

Challenge

Response

Examples

Staying close

to the customer

Managing in

a recession

Customer Relationship Teams

Senior-level communications

Global business

execution

Improved global

connectivity

ERP implementation

Geographic expansion

Opportunistic M&A

Building enhanced

strategic relationships

Leveraging

Phase I-IV core

competency

Global full-service FSPs

Preferred provider relationships

A c c e l e r a t i o n

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

N o r t h A m e r i c a •

E u r o p e •

A s i a / P a c i f i c •

L a t i n A m e r i c a •

A f r i c a

Summary

•

Align strategies with current market

•

Capitalize on opportunities to innovate customers business model

•

Enhance capability to deliver on a global scale

•

Be prepared to play anywhere along the partnership spectrum

•

Stay actively engaged to define the opportunities going forward

Kendle International (KNDL) Inactive 8-KRegulation FD Disclosure